Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.46 |
| ▸ | CSF1R | P07333 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575458 | 0.91 | PDE4B (0.48) | PDE4BCSF1R | |
| SCHEMBL23575567 | 0.90 | SIGMAR1 (0.43) | PDE4BCSF1R | |
| SCHEMBL23575578 | 0.86 | PDE4B (0.47) | PDE4BCSF1R | |
| SCHEMBL23575470 | 0.86 | CSF1R (0.51) | PDE4BCSF1R | |
| SCHEMBL23575445 | 0.83 | PDE4B (0.46) | PDE4BCSF1R | |
| SCHEMBL23575760 | 0.81 | PDE4B (0.43) | PDE4BCSF1R | |
| SCHEMBL23575817 | 0.78 | PDE4B (0.49) | PDE4BCSF1R | |
| SCHEMBL23575338 | 0.77 | PDE4B (0.58) | PDE4BCSF1R | |
| SCHEMBL23575367 | 0.77 | CSF1R (0.53) | PDE4BCSF1R | |
| SCHEMBL23575851 | 0.72 | PDE4B (0.56) | PDE4BCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | PDE4B 4033/4885CSF1R 3115/4885CYP3A4 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.